← Browse by Condition
Medical Condition

diffuse cutaneous systemic sclerosis

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for diffuse cutaneous systemic sclerosis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — diffuse cutaneous systemic sclerosis Clinical Trials

How many clinical trials are currently recruiting for diffuse cutaneous systemic sclerosis?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for diffuse cutaneous systemic sclerosis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for diffuse cutaneous systemic sclerosis?
diffuse cutaneous systemic sclerosis research spans Phase 1 (1 trial), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a diffuse cutaneous systemic sclerosis clinical trial?
Eligibility criteria for diffuse cutaneous systemic sclerosis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Top Sponsors
Mediar Therapeutics 1 trial
Miltenyi Biomedicine GmbH 1 trial
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 1 trial

Recruiting Clinical Trials

NCT07287670 Phase 2
Recruiting
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Enrollment
85 pts
Location
United States
Sponsor
Mediar Therapeutics
View Trial →
NCT06708845 Phase 1
Recruiting
US Zamto-cel Autoimmune Diseases
Enrollment
48 pts
Location
United States
Sponsor
Miltenyi Biomedicine GmbH
View Trial →
NCT05149768 Phase 2
Recruiting
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
Enrollment
11 pts
Location
Canada
Sponsor
London Health Sciences Centre ...
View Trial →

Related Conditions

lupus nephritis (1) systemic lupus erythematosus (1) systemic sclerosis ssc (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology